Organization (Industry)
PROCEPT BioRobotics Corp
ClinicalTrials.gov lists PROCEPT BioRobotics Corp as lead sponsor of 13 trials. It has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PROCEPT BioRobotics Corp: 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (2)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Prostatic Hyperplasia | 11 |
| Prostatic Neoplasms | 4 |
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2017 | 5 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Active Surveillance (study visit Day 1, Day 2 and Day 7) | Prostatic Neoplasms | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 2 of 2 on time (n=2) |
Journals published in (9)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BJU international | 6 |
| The Canadian journal of urology | 4 |
| Urology | 4 |
| The Journal of urology | 3 |
| Advances in therapy | 2 |
Showing 5 of 9 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 55 | 35 | 2025-12-23 |
SEC-reported annual financials (7)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 308,054,000 | -95,572,000 | 71,277,000 |
| 2024 | 224,498,000 | -91,413,000 | 62,298,000 |
| 2023 | 136,191,000 | -105,897,000 | 48,446,000 |
| 2022 | 75,014,000 | -87,154,000 | 28,981,000 |
| 2021 | 34,473,000 | -59,853,000 | 18,993,000 |
| 2020 | 7,717,000 | -53,019,000 | 16,275,000 |
| 2019 | not reported | not reported | not reported |
Financing and grant events (14)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2024-10-31 | Registered direct | 163,800,000 | Sec extracted |
| 2024-10-30 | Follow-on offering | 201,249,867 | Edgar offerings |
| 2024-10-30 | Registered direct | not disclosed | Sec extracted |
| 2024-10-28 | Other financing | not disclosed | Edgar offerings |
| 2023-08-04 | Public offering | 161,300,000 | Sec extracted |
Showing 5 of 14 events.
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| AQUABEAM Handpiece, REF: HP2000, a sterile single-use component of the AQUABEAM Robotic System. | Class II | 2021-07-09 |
| AquaBeam Handpiece, Sterile EO, Rx Only, REF: 310301, and 320301, a component of AquaBeam Robotic System. 320301 distributed outside the U.S. Device Description The AQUABEAM Robotic System is intended for use in patients suffering from lower urinary tract symptoms resulting from benign prostatic hyperplasia (BPH). | Class II | 2019-03-06 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2025-07-23 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| PROCEPT BioRobotics Corporation | San Jose, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (88)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 88 events.
Biomarker capability evidence (11)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KLK3 | Trial sponsor | Named in trial inclusion criteria |
| ASS1 | Trial collaborator | Named in trial exclusion criteria |
| KLK3 | Trial sponsor | Named in trial exclusion criteria |
| PVR | Trial sponsor | Exploratory endpoint in a trial |
| PVR | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 11 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, fda warning letters, fda untitled letters, fda inspection record, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.